Neurocrine Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1994
Net Income	369.7	249.7	154.5	89.6	407.3	37	Upgrade
Depreciation & Amortization	22.5	21.3	15.6	10.9	8.6	7.4	Upgrade
Share-Based Compensation	198.9	194.3	173.1	134.2	100	75.3	Upgrade
Other Operating Activities	54.3	-75.4	-3.8	21.8	-287.4	27.3	Upgrade
Operating Cash Flow	645.4	389.9	339.4	256.5	228.5	147	Upgrade
Operating Cash Flow Growth	153.40%	14.88%	32.32%	12.25%	55.44%	44.97%	Upgrade
Capital Expenditures	-31	-28.3	-16.5	-23.4	-10.9	-14.7	Upgrade
Acquisitions	0	0	-42.7	0	0	0	Upgrade
Change in Investments	-449	-438.8	-117.9	-106.8	15	-196.4	Upgrade
Investing Cash Flow	-480	-467.1	-177.1	-130.2	4.1	-211.1	Upgrade
Share Issuance / Repurchase	127	65.3	44.7	27.5	29.1	32.4	Upgrade
Debt Issued / Paid	0	0	-279	-0.1	-186.9	0	Upgrade
Financing Cash Flow	127	65.3	-234.3	27.4	-157.8	32.4	Upgrade
Exchange Rate Effect	0.3	0.3	-1.3	0	0	0	Upgrade
Net Cash Flow	292.7	-11.6	-73.3	153.7	74.8	-31.7	Upgrade
Free Cash Flow	614.4	361.6	322.9	233.1	217.6	132.3	Upgrade
Free Cash Flow Growth	158.91%	11.99%	38.52%	7.12%	64.47%	72.72%	Upgrade
Free Cash Flow Margin	31.00%	19.16%	21.69%	20.56%	20.81%	16.79%	Upgrade
Free Cash Flow Per Share	6.16	3.70	3.37	2.46	2.34	1.44	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).